Protalix BioTherapeutics (PLX) Total Current Liabilities (2010 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Total Current Liabilities of $27.4 million for Q1 2026, up 12.61% year-over-year from $24.3 million in Q1 2025, and up 3.28% quarter-over-quarter from $26.5 million in Q4 2025.
Protalix BioTherapeutics (PLX) Total Current Liabilities (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $27.4 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 12.61% year-over-year to $27.4 million; the TTM figure through Mar 2026 stood at $27.4 million (up 12.61% YoY), while the FY2025 annual figure was $26.5 million, up 3.5% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $27.4 million, up from $26.5 million in the prior quarter.
- The five-year high for Total Current Liabilities was $58.0 million in Q2 2024, with the low at $21.9 million in Q3 2025.
- The 5-year median for Total Current Liabilities is $31.0 million (2022), against an average of $33.1 million.
- The sharpest annual moves came in 2022 and 2024: Total Current Liabilities plunged 67.83% in 2022, then surged 150.86% in 2024.
- Protalix BioTherapeutics' Total Current Liabilities stood at $32.4 million in 2022, then soared by 40.4% to $45.5 million in 2023, then tumbled by 43.73% to $25.6 million in 2024, then advanced by 3.5% to $26.5 million in 2025, then climbed by 3.28% to $27.4 million in 2026.
- Business Quant data shows PLX's Total Current Liabilities at $27.4 million in Q1 2026, $26.5 million in Q4 2025, and $21.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | Protalix BioTherapeutics | 190.37 Mn | 149.71 Mn | 12.13 Mn | 31.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.39 Mn |
| Mar 31, 2026 | 27.39 Mn |
| Dec 31, 2025 | 26.52 Mn |
| Sep 30, 2025 | 21.95 Mn |
| Jun 30, 2025 | 24.09 Mn |
| Mar 31, 2025 | 24.32 Mn |
| Dec 31, 2024 | 25.62 Mn |
| Sep 30, 2024 | 24.22 Mn |
| Jun 30, 2024 | 57.97 Mn |
| Mar 31, 2024 | 54.83 Mn |
| Dec 31, 2023 | 45.53 Mn |
| Sep 30, 2023 | 43.36 Mn |
| Jun 30, 2023 | 23.11 Mn |
| Mar 31, 2023 | 31.52 Mn |
| Dec 31, 2022 | 32.43 Mn |
| Sep 30, 2022 | 34.30 Mn |
| Jun 30, 2022 | 30.96 Mn |
| Mar 31, 2022 | 35.33 Mn |
| Dec 31, 2021 | 33.18 Mn |
| Sep 30, 2021 | 42.76 Mn |